- Home
- IMMP vs AVIR Comparison
IMMP vs AVIR Comparison
Compare IMMP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- AVIR
- Stock Information
- Founded
- IMMP 1987
- AVIR 2012
- Country
- IMMP Australia
- AVIR United States
- Employees
- IMMP N/A
- AVIR N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- IMMP Health Care
- AVIR Health Care
- Exchange
- IMMP Nasdaq
- AVIR Nasdaq
- Market Cap
- IMMP 251.8M
- AVIR 290.4M
- IPO Year
- IMMP N/A
- AVIR 2020
- Fundamental
- Price
- IMMP $1.64
- AVIR $3.14
- Analyst Decision
- IMMP Buy
- AVIR Hold
- Analyst Count
- IMMP 1
- AVIR 1
- Target Price
- IMMP $7.00
- AVIR $6.00
- AVG Volume (30 Days)
- IMMP 87.8K
- AVIR 270.5K
- Earning Date
- IMMP 10-21-2025
- AVIR 11-06-2025
- Dividend Yield
- IMMP N/A
- AVIR N/A
- EPS Growth
- IMMP N/A
- AVIR N/A
- EPS
- IMMP N/A
- AVIR N/A
- Revenue
- IMMP $3,306,742.00
- AVIR N/A
- Revenue This Year
- IMMP N/A
- AVIR N/A
- Revenue Next Year
- IMMP $725.37
- AVIR N/A
- P/E Ratio
- IMMP N/A
- AVIR N/A
- Revenue Growth
- IMMP 31.28
- AVIR N/A
- 52 Week Low
- IMMP $1.32
- AVIR $2.46
- 52 Week High
- IMMP $2.71
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- IMMP 46.06
- AVIR 36.73
- Support Level
- IMMP $1.60
- AVIR $3.10
- Resistance Level
- IMMP $1.68
- AVIR $3.33
- Average True Range (ATR)
- IMMP 0.07
- AVIR 0.14
- MACD
- IMMP -0.00
- AVIR -0.03
- Stochastic Oscillator
- IMMP 28.12
- AVIR 6.47
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).